Pharmaceuticals, Biotech and Life Sciences - Intellectual Property

The pharma industry is highly competitive, with many companies across the globe working on similar medications and treatments. With more and more Canadian pharmaceutical companies launching new therapies and medications, it’s crucial that domestic firms protect their intellectual property and develop strategies that contribute to their success. At the same time, companies must be on top of any patent-related regulatory shifts, which can quickly change and make it more difficult for businesses to protect their products.

Osler has a long history of helping companies in the Pharmaceuticals, Biotech and Life Sciences sector safeguard their IP. For more than 11 years, we have represented one of the top three generic pharmaceutical companies worldwide in numerous pharmaceutical patent litigation proceedings under the Patented Medicines (Notice of Compliance) Regulations, and we’ve been involved in many other significant patent cases over the years. We also advise companies on how to negotiate licensing agreements and leverage their IP for M&A, reorganizations and other transactions.

With more people turning their attention to the biotech and life sciences space, it’s important to work with a group of legal advisors who understand the global healthcare market and can ensure that you maintain control over your work.

Recent experience

Mylan Pharmaceuticals ULC

Osler successfully represented Mylan Pharmaceuticals ULC in a patent proceeding brought by pharmaceutical company AstraZeneca. The Federal Court of Canada issued a decision in AstraZeneca Canada Inc. v Mylan Pharmaceuticals ULC that invalidated the patent relating to VIMOVO®, an anti-inflammatory combination drug.

Learn more about our work with Mylan Pharmaceuticals ULC
Pharmacist working at the prescription counter

Mylan Pharmaceuticals ULC

Osler successfully represented Mylan Pharmaceuticals in a patent proceeding brought by pharmaceutical company Amgen to prohibit the Minister of Health from issuing a market authorization (notice of compliance) to Mylan for its generic version of the drug SENSIPAR® (cinacalcet hydrochloride).

Learn more about our work with Mylan Pharmaceuticals
Medicine next to an empty pill bottle

Mylan Pharmaceuticals ULC

Mylan Pharmaceuticals ULC in an anti-inflammatory combination drug patent case.  Osler successfully represented Mylan in a patent proceeding brought by AstraZeneca. The Federal Court of Canada issued a decision in that invalidated the Canadian formulation patent relating to VIMOVO®, an anti-inflammatory combination drug.

Learn more about our work with Mylan Pharmaceuticals ULC
Pharmacy Hands with Pill Counter Tray and Bottle
Find more deals and cases

Download

Related service